Literature DB >> 2153430

Kaposi's sarcoma in immunosuppression. Possibly the result of a dual viral infection.

B Siegal1, S Levinton-Kriss, A Schiffer, J Sayar, I Engelberg, A Vonsover, Y Ramon, E Rubinstein.   

Abstract

Kaposi's sarcoma of the gingiva and skin developed in an HIV-negative renal transplant patient while he was receiving cyclosporine therapy. The Kaposi's sarcoma developed shortly after the patient had an acute infection with cytomegalovirus (CMV). Electron microscopy of the tumor's established cell line showed two types of virus-like particles. CMV DNA was identifiable in the cell line whereas infectious CMV could be isolated only after repeated passages (only after 3 months of culture). The other virus could not be identified, but did not appear to be either HIV or papilloma virus. The patient's tumor regressed after the discontinuation of cyclosporine therapy and the recovery from the acute CMV infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153430     DOI: 10.1002/1097-0142(19900201)65:3<492::aid-cncr2820650320>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus.

Authors:  R Sadler; L Wu; B Forghani; R Renne; W Zhong; B Herndier; D Ganem
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Protein arginine methyltransferase 1-directed methylation of Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen.

Authors:  Mel Campbell; Pei-Ching Chang; Steve Huerta; Chie Izumiya; Ryan Davis; Clifford G Tepper; Kevin Y Kim; Bogdan Shevchenko; Don-Hong Wang; Jae U Jung; Paul A Luciw; Hsing-Jien Kung; Yoshihiro Izumiya
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

3.  HIV-associated Kaposi's sarcoma: new developments in epidemiology and molecular pathology.

Authors:  W K Roth
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression.

Authors:  Zaklyah Kadry; Oscar Bronsther; David H Van Thiel; Parmjeet Randhawa; John J Fung; Thomas E Starzl
Journal:  Clin Transplant       Date:  1993-01-01       Impact factor: 2.863

5.  Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction.

Authors:  Jinjong Myoung; Don Ganem
Journal:  J Virol Methods       Date:  2011-03-17       Impact factor: 2.014

Review 6.  Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity?

Authors:  F Neipel; J C Albrecht; B Fleckenstein
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus.

Authors:  J Vieira; P O'Hearn; L Kimball; B Chandran; L Corey
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

8.  Opposing roles of RNA receptors TLR3 and RIG-I in the inflammatory response to double-stranded RNA in a Kaposi's sarcoma cell line.

Authors:  April J Livengood; Christina C N Wu; Dennis A Carson
Journal:  Cell Immunol       Date:  2007-12-26       Impact factor: 4.868

9.  Nuclear Innate Immune DNA Sensor IFI16 Is Degraded during Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus (KSHV): Role of IFI16 in Maintenance of KSHV Latency.

Authors:  Arunava Roy; Dipanjan Dutta; Jawed Iqbal; Gina Pisano; Olsi Gjyshi; Mairaj Ahmed Ansari; Binod Kumar; Bala Chandran
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 10.  Human herpesvirus-8: detection of novel herpesvirus-like DNA sequences in Kaposi's sarcoma and other lesions.

Authors:  O M Memar; P L Rady; S K Tyring
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.